X

Trial Profile

A Multicenter, Open-label, Single-arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Neonates With Repeated Electroencephalographic Seizures

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 18 Jan 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brivaracetam (Primary) ; Brivaracetam (Primary)
Indications Neonatal seizures
Focus Pharmacokinetics
Acronyms PETITE
Sponsors UCB Biopharma

Most Recent Events

22 Jul 2022 This trial has been completed in Hungary (End Date: 29 May 2021) according to European Clinical Trials Database record.
21 Feb 2022 Status changed to discontinued due to due to enrolment challenges.
20 Jan 2022 This trial has been discontinued in Belgium (Date of the global end of the trial : 23-Dec-2021), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com